Chesterfield, MO, United States of America

Cathleen Elizabeth Hanau

USPTO Granted Patents = 16 (Patent Applications = 1)

CIPO Patents = 1

EPO Patents = 3 (Patent Applications = 3)

Average Co-Inventor Count = 19.1

ph-index = 11

Forward Citations = 395(Granted Patents)

Location History:

St. Louis, MO (US) (2000 - 2006)
Chesterfield, MO (US) (2002 - 2012)

Company Filing History:

10 out of 1,323

G.d. Searle & Company

patents

3 out of 220

Pharmacia Corporation

Pharmacia Corporation (of Pfizer, Inc.)

patents

Years Active: 2000-2012

Loading Chart...

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8106197 - Aminoheteroaryl compounds as protein kinase inhibitors (2012-01-31),

2. 7230098 - Aminoheteroaryl compounds as protein kinase inhibitors (2007-06-12),

3. 7153959 - Substituted pyrazoles as p38 kinase inhibitors (2006-12-26),

4. 7138411 - Substituted benzopyran derivatives for the treatment of inflammation (2006-11-21),

5. 7109211 - Substituted benzopyran derivatives for the treatment of inflammation (2006-09-19),

6. 7071198 - Substituted pyrazoles as p38 kinase inhibitors (2006-07-04),

7. 6979686 - Substituted pyrazoles as p38 kinase inhibitors (2005-12-27),

8. 6806288 - Substituted benzopyran derivatives for the treatment (2004-10-19),

9. 6617324 - Substituted pyrazoles as p38 kinase inhibitors (2003-09-09),

10. 6525059 - Substituted pyrazoles as p38 kinase inhibitors (2003-02-25),

11. 6514977 - Substituted pyrazoles as p38 kinase inhibitors (2003-02-04),

12. 6492390 - Substituted benzopyran analogs for the treatment of inflammation (2002-12-10),

13. 6423713 - Substituted pyrazoles as p38 kinase inhibitors (2002-07-23),

14. 6271253 - Substituted benzopyran derivatives for the treatment of inflammation (2001-08-07),

15. 6077850 - Substituted benzopyran analogs for the treatment of inflammation (2000-06-20),

Title: Inventor Spotlight: Cathleen Elizabeth Hanau

Introduction

Cathleen Elizabeth Hanau is a distinguished inventor based in Chesterfield, MO, USA. With a remarkable portfolio of 16 patents, he has significantly contributed to the field of medicinal chemistry, particularly in the development of innovative compounds with therapeutic applications.

Latest Patents

His most recent patents include groundbreaking research into aminoheteroaryl compounds as protein kinase inhibitors. Specifically, he has developed aminopyridine and aminopyrazine compounds that show potential for use in inhibiting c-MET, a target associated with various forms of cancer. These compounds, along with their compositions and methods of use, represent a critical advancement in the cancer treatment landscape.

Career Highlights

Throughout his career, Cathleen has worked with prominent companies such as G.D. Searle & Company and Pharmacia Corporation. His dedication to advancing pharmaceutical science is evident in his commitment to developing novel therapeutic agents aimed at improving patient health outcomes.

Collaborations

Cathleen has collaborated with notable colleagues in his field, including Matthew James Graneto and Suzanne S. Metz. These partnerships have allowed him to leverage diverse expertise and drive forward innovations that enhance drug efficacy and safety.

Conclusion

In summary, Cathleen Elizabeth Hanau stands out as a key figure in the realm of invention and innovation. His contributions to the development of protein kinase inhibitors not only highlight his expertise but also underscore the importance of collaborative efforts in advancing medical science.

This text is generated by artificial intelligence and may not be accurate.